Topics:

Phase II Study Reports Positive Results for Topical Treatment of Superficial Basal Cell Carcinoma

Phase II Study Reports Positive Results for Topical Treatment of Superficial Basal Cell Carcinoma

A study published in the Journal of the American Academy of Dermatology (44:807-813, 2001) reported an almost 90% clearance of superficial basal cell carcinoma following daily application of imiquimod (Aldara) 5% cream for 6 weeks.

In this multicenter, phase II trial conducted in Australia and New Zealand, 99 patients applied imiquimod to a single biopsy-proven superficial basal cell carcinoma tumor. Treatment efficacy was measured by complete histologic clearance of the carcinoma in the posttreatment biopsy. Of the 33 patients using the once-daily regimen, 87.9% showed complete clearance of superficial tumor. The most frequently reported reactions were itching, pain, and discharge at the target tumor site. With the exception of itching, which was reported by almost the same percentage of patients in both regimens, the percentage of patients reporting pain and discharge decreased as dosing frequency decreased.

 
Loading comments...
Please Wait 20 seconds or click here to close